Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy

Abstract

PURPOSE Radical nephroureterectomy (RNU) is a standard treatment for upper urinary tract urothelial carcinoma. However, RNU can result in decreased renal function and cannot be treated with adjuvant chemotherapy. We performed a risk group stratification analysis to determine the preoperative factors that are predictive of diminished renal function after RNU. MATERIALS AND METHODS We retrospectively evaluated the medical records of all patients who underwent nephroureterectomy for upper urinary tract urothelial carcinoma at the Chang Gung Memorial Hospital from 2001 to 2008. We analyzed the association between perioperative glomerular filtration rate and preoperative parameters including cancer characteristics, serum creatinine level, and kidney size measured on computed tomographic images. RESULTS A total of 242 patients fulfilled the inclusion criteria. The average decrease in renal function 1 month after RNU was 19.7%. Using 60 mL/min/1.73 m(2) as the eligibility cutoff for cisplatin-based chemotherapy, 42.1% of the population was eligible prior to nephroureterectomy, whereas following surgery only 15.2% remained eligible. Using a cutoff of 45 mL/min/1.73 m(2), 59.9% of the cohort was eligible for fractionated cisplatin dosing preoperatively, whereas only 32.6% remained above the cutoff postoperatively. The most significant predictors of poor postoperative renal function were body mass index >25 kg/m(2), age >65 years, contralateral kidney length less than 10 cm, and absence of ipsilateral hydronephrosis. CONCLUSION Our results suggest that older age, higher body mass index, smaller contralateral renal length, and absence of ipsilateral hydronephrosis are predictive of decreased renal function after RNU.

DOI: 10.2147/DDDT.S72197

Extracted Key Phrases

4 Figures and Tables

0500100020162017
Citations per Year

294 Citations

Semantic Scholar estimates that this publication has 294 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Shao2014RiskFA, title={Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy}, author={I. Shao and Yu-Hsiang Lin and Chen-pang Hou and Horng-heng Juang and Chien-Lun Chen and Phei-Lang Chang and Ke-Hung Tsui}, booktitle={Drug design, development and therapy}, year={2014} }